Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 288
- Registration Number
- NCT04085172
- Locations
- 🇦🇹
LKH-Klinikum Graz, Graz, Austria
🇦🇹Medizinische Universtität Wien, Vienna, Austria
🇵🇹Hospital de Cascais - Dr. José de Almeida, Alcabideche, Portugal
Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome
- Conditions
- Prader-Willi Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT04066088
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin
- Conditions
- Affective Dysregulation
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 40
- Registration Number
- NCT04016207
Guanfacine to Improve Substance Use Outcomes in Women
- Conditions
- Substance Use Disorders
- Interventions
- Other: Behavioral Counseling
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Yale University
- Target Recruit Count
- 74
- Registration Number
- NCT03980184
- Locations
- 🇺🇸
The Yale Stress Center: Yale University, New Haven, Connecticut, United States
Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT03865940
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Yale University
- Target Recruit Count
- 160
- Registration Number
- NCT03764098
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
- Conditions
- Attention Deficit Disorder
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT03662763
- Locations
- 🇳🇱
Maastricht University Medical Centre, Maastricht, Netherlands
Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents
- Conditions
- ADHD
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- King's College London
- Target Recruit Count
- 20
- Registration Number
- NCT03333668
- Locations
- 🇬🇧
Institute of Psychiatry, Psychology & Neuroscience; King's College London, London, United Kingdom
Guanfacine Extended Release and Mindfulness Skills Therapy
- Conditions
- Stress Disorder
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- UConn Health
- Registration Number
- NCT03258476
- Locations
- 🇺🇸
UConn Health, Farmington, Connecticut, United States
Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
- Conditions
- Alcohol Abstinence
- Interventions
- Drug: Placebo (for guanfacine)
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 32
- Registration Number
- NCT03137082
- Locations
- 🇺🇸
The Health Sciences Center, Stony Brook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.